rheumatology
Medicines

Tocilizumab shortage in Australia as WHO approves use for COVID-19

Australia is facing a shortage of tocilizumab (Actemra) until at least September due to a surge in global demand for its use in treating COVID-19 patients. Roche Australia has written to rheumatologists to advise that as of July 5 there was “an immediate shortage” of Actemra IV 200mg in Australia, and the company anticipated a ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic